Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus.

Autor: Hutton DW; Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor, MI, USA. Electronic address: dwhutton@umich.edu., Prosser LA; Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor, MI, USA; Child Health Evaluation and Research Center (CHEAR), University of Michigan, Ann Arbor, MI, USA., Rose AM; Child Health Evaluation and Research Center (CHEAR), University of Michigan, Ann Arbor, MI, USA., Mercon K; Child Health Evaluation and Research Center (CHEAR), University of Michigan, Ann Arbor, MI, USA., Ortega-Sanchez IR; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Leidner AJ; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Havers FP; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Prill MM; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Whitaker M; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Roper LE; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Pike J; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Britton A; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Melgar M; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Publikováno v: Vaccine [Vaccine] 2024 Oct 24; Vol. 42 (24), pp. 126294. Date of Electronic Publication: 2024 Sep 05.

Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.

Autor: Fleming-Dutra KE, Jones JM, Roper LE, Prill MM, Ortega-Sanchez IR, Moulia DL, Wallace M, Godfrey M, Broder KR, Tepper NK, Brooks O, Sánchez PJ, Kotton CN, Mahon BE, Long SS, McMorrow ML

Publikováno v: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2023 Oct 13; Vol. 72 (41), pp. 1115-1122. Date of Electronic Publication: 2023 Oct 13.

Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.

Autor: Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, Sánchez PJ, Kotton CN, Mahon BE, Meyer S, Long SS, McMorrow ML

Publikováno v: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2023 Aug 25; Vol. 72 (34), pp. 920-925. Date of Electronic Publication: 2023 Aug 25.

Safety and Effectiveness of Maternal COVID-19 Vaccines Among Pregnant People and Infants.

Autor: Fleming-Dutra KE; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-9 Atlanta, GA 30329, USA. Electronic address: ftu2@cdc.gov., Zauche LH; Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Roper LE; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-9 Atlanta, GA 30329, USA., Ellington SR; Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA., Olson CK; Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; U.S. Public Health Service Commissioned Corps, Atlanta, GA, USA., Sharma AJ; Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; U.S. Public Health Service Commissioned Corps, Atlanta, GA, USA., Woodworth KR; Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA., Tepper N; U.S. Public Health Service Commissioned Corps, Atlanta, GA, USA; Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA., Havers F; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-9 Atlanta, GA 30329, USA; U.S. Public Health Service Commissioned Corps, Atlanta, GA, USA., Oliver SE; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-9 Atlanta, GA 30329, USA; U.S. Public Health Service Commissioned Corps, Atlanta, GA, USA., Twentyman E; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-9 Atlanta, GA 30329, USA., Jatlaoui TC; U.S. Public Health Service Commissioned Corps, Atlanta, GA, USA; Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Publikováno v: Obstetrics and gynecology clinics of North America [Obstet Gynecol Clin North Am] 2023 Jun; Vol. 50 (2), pp. 279-297. Date of Electronic Publication: 2023 Feb 21.

Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.

Autor: Link-Gelles R, Ciesla AA, Roper LE, Scobie HM, Ali AR, Miller JD, Wiegand RE, Accorsi EK, Verani JR, Shang N, Derado G, Britton A, Smith ZR, Fleming-Dutra KE

Publikováno v: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2023 Feb 03; Vol. 72 (5), pp. 119-124. Date of Electronic Publication: 2023 Feb 03.